Palladium nanoplate-based IL-6R antagonists have been designed to deliver tocilizumab to the liver for hepcidin suppression, which alleviates cancer-associated anemia and simultaneously inhibits tumor progression, partly due to corrected anemia, in murine models [145]. Here, IL6R is linked to anemia (phenotype).